Image guided hypofractionated radiotherapy by Helical Tomotherapy for prostate carcinoma: Toxicity and impact on nadir PSA - Abstract

AIM: To evaluate the toxicity of a hypofractionated schedule for primary radiotherapy (RT) of prostate cancer as well as the value of the nadir PSA (nPSA) and time to nadir PSA (tnPSA) as surrogate efficacy of treatment.

MATERIAL AND METHODS: Eighty patients underwent hypofractionated schedule by Helical Tomotherapy (HT). A dose of 70.2 Gy was administered in 27 daily fractions of 2.6 Gy. Acute and late toxicities were graded on the RTOG/EORTC scales. The nPSA and the tnPSA for patients treated with exclusive RT were compared to an equal cohort of 20 patients treated with conventional fractionation and standard conformal radiotherapy.

RESULTS: Most of patients (83%) did not develop acute gastrointestinal (GI) toxicity and 50% did not present genitourinary (GU) toxicity. After a median follow-up of 36 months only grade 1 of GU and GI was reported in 6 and 3 patients as late toxicity. Average tnPSA was 30 months. The median value of nPSA after exclusive RT with HT was 0.28 ng/mL and was significantly lower than the median nPSA (0.67 ng/mL) of the conventionally treated cohort (P = 0.02).

CONCLUSIONS: Hypofractionated RT schedule with HT for prostate cancer treatment reports very low toxicity and reaches a low level of nPSA that might correlate with good outcomes.

Written by:
Barra S, Vagge S, Marcenaro M, Blandino G, Timon G, Vidano G, Agnese D, Gusinu M, Cavagnetto F, Corvò R.   Are you the author?
Department of Radiation Oncology, IRCCS San Martino-IST, National Cancer Research Institute, 16100 Genoa, Italy; University of Genoa, DISSAL, 16100 Genoa, Italy; Department of Medical Physics, IRCCS San Martino-IST, National Cancer Research Institute, Genova, Italy.

Reference: Biomed Res Int. 2014;2014:541847.
doi: 10.1155/2014/541847


PubMed Abstract
PMID: 24745018

UroToday.com Prostate Cancer Section